Firms across the healthcare sector are working day and night to develop the first approved treatment for patients with Covid-19 — and, in the UK, BerGenBio looks to be a leading name in this particular race.

 At the end of April, the Norwegian biotech company had its daily oral drug bemcentinib fast-tracked towards Phase II clinical trials by the government-funded ACCORD (Accelerating Covid-19 Research & Development platform) study.

 We take a closer look at the work BerGenBio has done to become one of the firms at the forefront of the UK’s hunt for an effective virus treatment.

Read the full article here.